Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and epilepsy:

Search results

Items: 1 to 20 of 240

1.

Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.

Dale T, Downs J, Olson H, Bergin AM, Smith S, Leonard H.

Epilepsy Res. 2019 Feb 5;151:31-39. doi: 10.1016/j.eplepsyres.2019.02.001. [Epub ahead of print] Review.

PMID:
30771550
2.

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C.

Epilepsia. 2019 Feb 11. doi: 10.1111/epi.14670. [Epub ahead of print]

PMID:
30740695
3.

Development of a validated method for the qualitative and quantitative analysis of cannabinoids in plant biomass and medicinal cannabis resin extracts obtained by super-critical fluid extraction.

Elkins AC, Deseo MA, Rochfort S, Ezernieks V, Spangenberg G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 30;1109:76-83. doi: 10.1016/j.jchromb.2019.01.027. [Epub ahead of print]

PMID:
30738340
4.

An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine.

Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O.

Pain Ther. 2019 Feb 5. doi: 10.1007/s40122-019-0114-4. [Epub ahead of print] Review.

PMID:
30721403
5.

Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?

Kollmyer DM, Wright KE, Warner NM, Doherty MJ.

Epilepsy Behav Case Rep. 2018 Dec 3;11:52-53. doi: 10.1016/j.ebcr.2018.11.007. eCollection 2019.

6.

Corrigendum: Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.

Pamplona FA, da Silva LR, Coan AC.

Front Neurol. 2019 Jan 10;9:1050. doi: 10.3389/fneur.2018.01050. eCollection 2018.

7.

Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex.

Serra I, Scheldeman C, Bazelot M, Whalley BJ, Dallas ML, de Witte PAM, Williams CM.

Behav Brain Res. 2019 May 2;363:135-144. doi: 10.1016/j.bbr.2019.01.040. Epub 2019 Jan 23.

PMID:
30684511
8.

Cannabidiol (Epidiolex) for epilepsy.

[No authors listed]

Med Lett Drugs Ther. 2018 Nov 5;60(1559):182-184. No abstract available.

PMID:
30681657
9.

Cannabinoid therapy in epilepsy.

Billakota S, Devinsky O, Marsh E.

Curr Opin Neurol. 2019 Jan 22. doi: 10.1097/WCO.0000000000000660. [Epub ahead of print]

PMID:
30676535
10.

Cannabidiol in Anxiety and Sleep: A Large Case Series.

Shannon S, Lewis N, Lee H, Hughes S.

Perm J. 2019;23. pii: 18-041. doi: 10.7812/TPP/18-041.

11.

Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Chen JW, Borgelt LM, Blackmer AB.

Ann Pharmacother. 2019 Jan 8:1060028018822124. doi: 10.1177/1060028018822124. [Epub ahead of print]

PMID:
30616356
12.

Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus.

Rajaraman RR, Sankar R, Hussain SA.

Epilepsy Behav Case Rep. 2018 Jul 17;10:141-144. doi: 10.1016/j.ebcr.2018.07.004. eCollection 2018.

13.

Multigenerational consequences of early-life cannabinoid exposure in zebrafish.

Carty DR, Miller ZS, Thornton C, Pandelides Z, Kutchma ML, Willett KL.

Toxicol Appl Pharmacol. 2019 Feb 1;364:133-143. doi: 10.1016/j.taap.2018.12.021. Epub 2018 Dec 27.

PMID:
30594692
14.

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models.

Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ.

Epilepsia. 2019 Feb;60(2):303-314. doi: 10.1111/epi.14629. Epub 2018 Dec 26.

PMID:
30588604
15.

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.

Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C.

Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018 Dec 23.

PMID:
30582156
16.

Simultaneous quantification of thirteen cannabinoids and metabolites in human plasma by liquid chromatography tandem mass spectrometry in adult epilepsy patients.

Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK.

Ther Drug Monit. 2018 Dec 4. doi: 10.1097/FTD.0000000000000583. [Epub ahead of print]

PMID:
30520828
17.

Cannabis-based products for pediatric epilepsy: A systematic review.

Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, Alexander C, Repetski AE, Shukla V, McCoy B, Wells GA.

Epilepsia. 2019 Jan;60(1):6-19. doi: 10.1111/epi.14608. Epub 2018 Dec 4.

PMID:
30515765
18.

Emerging drugs for the treatment of Dravet syndrome.

Brigo F, Striano P, Balagura G, Belcastro V.

Expert Opin Emerg Drugs. 2018 Nov 27. doi: 10.1080/14728214.2018.1552937. [Epub ahead of print]

PMID:
30482063
19.

Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.

Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR.

CNS Drugs. 2019 Jan;33(1):47-60. doi: 10.1007/s40263-018-0589-2.

PMID:
30460546
20.

Cannabis for the treatment of paediatric epilepsy? An update for Canadian paediatricians.

James Huntsman R, Tang-Wai R, Acton B, Alcorn J, William Lyon A, David Mousseau D, Seifert B, Laprairie R, Prosser-Loose E, Ondrej Hanuš L.

Paediatr Child Health. 2018 Sep;23(6):368-373. doi: 10.1093/pch/pxy036. Epub 2018 Apr 5.

PMID:
30455572

Supplemental Content

Loading ...
Support Center